Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.77 |
| ▸ | HCRTR1 | O43613 | 18/20 | 0.59 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15058357 | 1.00 | CYP3A4 (0.77) | CYP3A4HCRTR1HCRTR2 | |
| SCHEMBL15058407 | 0.91 | CYP3A4 (0.71) | CYP3A4HCRTR1HCRTR2 | |
| SCHEMBL15058405 | 0.91 | CYP3A4 (0.71) | CYP3A4HCRTR1HCRTR2 | |
| SCHEMBL15058031 | 0.87 | CYP3A4 (1.00) | CYP3A4HCRTR1HCRTR2 | |
| SCHEMBL15058032 | 0.87 | CYP3A4 (1.00) | CYP3A4HCRTR1HCRTR2 | |
| SCHEMBL934650 | 0.86 | CYP3A4 (0.69) | CYP3A4HCRTR1HCRTR2 | |
| SCHEMBL934652 | 0.86 | CYP3A4 (0.69) | CYP3A4HCRTR1HCRTR2 | |
| SCHEMBL934699 | 0.84 | CYP3A4 (0.62) | CYP3A4HCRTR1HCRTR2 | |
| SCHEMBL935121 | 0.84 | CYP3A4 (0.62) | CYP3A4HCRTR1HCRTR2 | |
| SCHEMBL934698 | 0.84 | CYP3A4 (0.62) | CYP3A4HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794593-B1 | SPIRO AMINIC COMPOUNDS AS OREXIN ANTAGONISTS | Rottapharm Biotech Srl (IT) | 2017-02-01 | — | — | EP | claimed |
| US-9062033-B2 | Chemical compounds | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-06-23 | — | — | US | claimed |
| US-20140357653-A1 | CHEMICAL COMPOUNDS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-12-04 | — | — | US | claimed |
| EP-2794593-A1 | CHEMICAL COMPOUNDS | Rottapharm Biotech S.r.l. (IT) | 2014-10-29 | — | — | EP | claimed |
| WO-2013092893-A1 | CHEMICAL COMPOUNDS | ROTTAPHARM SPA (IT) | 2013-06-27 | — | — | WO | claimed |
| EP-2794593-B1 | SPIRO AMINIC COMPOUNDS AS OREXIN ANTAGONISTS | Rottapharm Biotech Srl (IT) | 2017-02-01 | — | — | EP | disclosed |
| EP-2794593-B1 | SPIRO AMINIC COMPOUNDS AS OREXIN ANTAGONISTS | Rottapharm Biotech Srl (IT) | 2017-02-01 | — | — | EP | disclosed |
| US-9062033-B2 | Chemical compounds | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-06-23 | — | — | US | disclosed |
| US-9062033-B2 | Chemical compounds | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-06-23 | — | — | US | disclosed |
| US-9062033-B2 | Chemical compounds | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-06-23 | — | — | US | disclosed |
| US-20140357653-A1 | CHEMICAL COMPOUNDS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-12-04 | — | — | US | disclosed |
| US-20140357653-A1 | CHEMICAL COMPOUNDS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-12-04 | — | — | US | disclosed |
| US-20140357653-A1 | CHEMICAL COMPOUNDS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-12-04 | — | — | US | disclosed |
| EP-2794593-A1 | CHEMICAL COMPOUNDS | Rottapharm Biotech S.r.l. (IT) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013092893-A1 | CHEMICAL COMPOUNDS | ROTTAPHARM SPA (IT) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013092893-A1 | CHEMICAL COMPOUNDS | ROTTAPHARM SPA (IT) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357653-A1 | CHEMICAL COMPOUNDS | HCRTR2, HCRTR1, NPY1R | CYP3A4 1477/4885HCRTR1 2/4885HCRTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.